RxDoctor Payments Data

Jonathan Gonenne, MD

Gastroenterology · Springfield, ORNPI 1649299538

Payments from drug & device makers

$877in general payments, 2019–2025

Across 31 payments — averaging $28.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$348
  • Takeda Pharmaceuticals U.S.A., Inc.$115
  • Boston Scientific$95
  • Sanofi$70
  • Braintree Laboratories, Inc.$55
  • Pfizer$47
  • plus $146 from 5 others

What the payments were for

  • Food & beverage$84797%
  • Education$303%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$877 in reported general payments places this provider in the 60th percentile of 220 gastroenterology providers in Oregon.

See all gastroenterology providers in Oregon

Medicare billing

Part B allowed, 2024
$98,292
Medicare patients
350
Services billed
960

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab15$398,362
Skyrizi On-BodyRisankizumab-Rzaa13$246,622
XifaxanRifaximin47$148,556
RinvoqUpadacitinib12$128,384
Humira(Cf) PenAdalimumab13$90,454
CreonLipase/Protease/Amylase26$88,795
Mesalamine101$48,694
VemlidyTenofovir Alafenamide15$21,758
LinzessLinaclotide20$12,897
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg212$5,656
Budesonide DrBudesonide32$5,199
SutabSod Sulf/Pot Chloride/Mag Sulf27$4,367
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates52$3,442
Ursodiol35$2,902
Colestipol Hcl20$2,085

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$45$398,36215 claims
AbbVieRinvoq, Creon, Linzess$348$230,07658 claims
Braintree Laboratories, Inc.Sutab$55$4,36727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 220 gastroenterology providers in Oregon.

Other gastroenterology in Springfield

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →